130 related articles for article (PubMed ID: 19906783)
1. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome.
Tan S; Bechmann LP; Benson S; Dietz T; Eichner S; Hahn S; Janssen OE; Lahner H; Gerken G; Mann K; Canbay A
J Clin Endocrinol Metab; 2010 Jan; 95(1):343-8. PubMed ID: 19906783
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.
Setji TL; Holland ND; Sanders LL; Pereira KC; Diehl AM; Brown AJ
J Clin Endocrinol Metab; 2006 May; 91(5):1741-7. PubMed ID: 16492691
[TBL] [Abstract][Full Text] [Related]
3. Non-alcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS).
Hossain N; Stepanova M; Afendy A; Nader F; Younossi Y; Rafiq N; Goodman Z; Younossi ZM
Scand J Gastroenterol; 2011 Apr; 46(4):479-84. PubMed ID: 21114431
[TBL] [Abstract][Full Text] [Related]
4. [Prevalence of nonalcoholic fatty liver disease in patients with polycystic ovary syndrome: a case-control study].
Zheng RH; Ding CF
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):98-101. PubMed ID: 18683746
[TBL] [Abstract][Full Text] [Related]
5. Chronic inflammation and elevated homocysteine levels are associated with increased body mass index in women with polycystic ovary syndrome.
Guzelmeric K; Alkan N; Pirimoglu M; Unal O; Turan C
Gynecol Endocrinol; 2007 Sep; 23(9):505-10. PubMed ID: 17852421
[TBL] [Abstract][Full Text] [Related]
6. [Exploration of the classification of polycystic ovarian syndrome].
Lin JF; Li X; Zhu MW
Zhonghua Fu Chan Ke Za Zhi; 2006 Oct; 41(10):684-8. PubMed ID: 17199924
[TBL] [Abstract][Full Text] [Related]
7. [Polycystic ovarian syndrome incidence in young women with non-alcoholic fatty liver disease].
Ciotta L; Pagano I; Stracquadanio M; Formuso C
Minerva Ginecol; 2011 Oct; 63(5):429-37. PubMed ID: 21926952
[TBL] [Abstract][Full Text] [Related]
8. Atherogenic changes in low-density lipoprotein particle profiles were not observed in non-obese women with polycystic ovary syndrome.
Kim JJ; Chae SJ; Choi YM; Hwang KR; Song SH; Yoon SH; Kim SM; Ku SY; Kim SH; Kim JG; Moon SY
Hum Reprod; 2013 May; 28(5):1354-60. PubMed ID: 23477907
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Gambarin-Gelwan M; Kinkhabwala SV; Schiano TD; Bodian C; Yeh HC; Futterweit W
Clin Gastroenterol Hepatol; 2007 Apr; 5(4):496-501. PubMed ID: 17287148
[TBL] [Abstract][Full Text] [Related]
10. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children.
Feldstein AE; Alkhouri N; De Vito R; Alisi A; Lopez R; Nobili V
Am J Gastroenterol; 2013 Sep; 108(9):1526-31. PubMed ID: 23752877
[TBL] [Abstract][Full Text] [Related]
12. Low prevalence of the metabolic syndrome but high occurrence of various metabolic disorders in Chinese women with polycystic ovary syndrome.
Ni RM; Mo Y; Chen X; Zhong J; Liu W; Yang D
Eur J Endocrinol; 2009 Sep; 161(3):411-8. PubMed ID: 19542239
[TBL] [Abstract][Full Text] [Related]
13. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome.
Vassilatou E; Lafoyianni S; Vryonidou A; Ioannidis D; Kosma L; Katsoulis K; Papavassiliou E; Tzavara I
Hum Reprod; 2010 Jan; 25(1):212-20. PubMed ID: 19887498
[TBL] [Abstract][Full Text] [Related]
14. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
15. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M
Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091
[TBL] [Abstract][Full Text] [Related]
16. Dietary glycemic index is associated with less favorable anthropometric and metabolic profiles in polycystic ovary syndrome women with different phenotypes.
Graff SK; Mário FM; Alves BC; Spritzer PM
Fertil Steril; 2013 Oct; 100(4):1081-8. PubMed ID: 23830153
[TBL] [Abstract][Full Text] [Related]
17. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
18. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance.
Jones H; Sprung VS; Pugh CJ; Daousi C; Irwin A; Aziz N; Adams VL; Thomas EL; Bell JD; Kemp GJ; Cuthbertson DJ
J Clin Endocrinol Metab; 2012 Oct; 97(10):3709-16. PubMed ID: 22837189
[TBL] [Abstract][Full Text] [Related]
19. Central arterial stiffness and diastolic dysfunction are associated with insulin resistance and abdominal obesity in young women but polycystic ovary syndrome does not confer additional risk.
Rees E; Coulson R; Dunstan F; Evans WD; Blundell HL; Luzio SD; Dunseath G; Halcox JP; Fraser AG; Rees DA
Hum Reprod; 2014 Sep; 29(9):2041-9. PubMed ID: 25035436
[TBL] [Abstract][Full Text] [Related]
20. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
